A new study by Truveta, published in JAMA Internal Medicine, shows that tirzepatide, or Mounjaro, leads to significantly more weight loss than semaglutide, or Ozempic. Analyzing over 18,000 adults with overweight or obesity, the study found that 82% of tirzepatide users lost at least 5% of their body weight after one year, compared to 67% of semaglutide users, and tirzepatide users also had double the average weight loss at one year.
Full Story: CNN (7/8)